

Supplement 6. The most frequently reported PIPs or medication classes reported in systematic reviews

Review	No. of primary studies conducted in community settings	PIM	PPO
Malakouti et al. ²⁹ (2021)	10	Benzodiazepines, NSAIDs, amitriptyline	NR
Ude-Okeleke et al. ³¹ (2021)	2	NSAIDs, allopurinol, antihypertensives, Benzodiazepine, digoxin, tricyclic, antidepressants, antihistamine, anti-thrombotic anti-inflammatory, psycholeptics and psychoanaleptics	NR
Thomas and Thomas ³⁰ (2019)*	22	Benzodiazepines, Hypnotics, NSAIDs, PPIs	Angiotensin-converting-enzymes with heart failure or coronary artery disease; anti-platelet or statin therapy with coronary, cerebral or peripheral vascular disease; bone anti-resorptive; anti-depressants; fiber for diverticulosis; anti-resorptive or anabolic therapy for osteoporosis; vitamin D with Ca; agonist for asthma or COPD; pneumococcal vaccine, influenza vaccine; DMARDs; increased after comprehensive geriatric assessment vitamin D, vitamin B12; anti-depressants, trazodone
Thomas ¹⁴ (2016)	10	Benzodiazepines, PPIs, NSAIDs	Untreated hypertension; failure to use antiplatelet medication; failure to treat osteoporosis
Tommelein et al. ⁵ (2015)	52	Anxiolytics (benzodiazepine derivatives and diazepam), antidepressants (amitriptyline and doxepin), NSAIDs (indomethacin)	Omission of antiplatelet therapy in DM with co-existing major cardiovascular risk factors; omission of Ca and vitamin D supplement in patients with known osteoporosis; omission of Statin therapy in DM if coexisting major cardiovascular risk factors present; omission of metformin with DMII ± metabolic syndrome; omission of statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, where the patient's functional status remains independent for activities of daily living and life expectancy is >5 years; omission of β-blockers with chronic stable angina
Hill-Taylor et al. ²³ (2013)	2	PPIs, benzodiazepines, NSAIDs	Antiplatelet/arterial diseases, vitamin D/osteoporosis, statins/vascular diseases
Opondo et al. ²² (2012)	19	Propoxyphene, doxazosin, diphenhydramine, Amitriptyline	NR
Guaraldo et al. ²⁴ (2011)	19	Amitriptyline, propoxyphene, cyclobenzaprine	NR
Liu and Christensen ¹³ (2002)	7	Propoxyphene, amitriptyline, benzodiazepines	NR

PIP, potentially inappropriate prescribing; PIM, potentially inappropriate medications; PPO, potential prescribing omissions; NSAIDs, non-steroidal anti-inflammatory drugs; PPIs, proton-pump inhibitors; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; DMARDs, disease-modifying antirheumatic drugs; NR, not reported.

*PPO reported from 6 primary studies.